TipRanks on MSN
aTyr Pharma Reports Increased Losses Amid Rising R&D Costs
Atyr Pharma Inc. ( ($ATYR) ) has released its Q3 earnings. Here is a breakdown of the information Atyr Pharma Inc. presented to its investors.
Results reported for Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis. Company plans to meet with the FDA to ...
SAN DIEGO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback